Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

Bayer says U.S. plaintiffs on glyphosate more than double since July

Stock Markets Oct 30, 2019 05:53AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Logo of Bayer AG at a plant of the German pharmaceutical and chemical maker in Wuppertal
 
BAYGN
-0.39%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MON
0.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Ludwig Burger

FRANKFURT (Reuters) - Germany's Bayer (DE:BAYGn) is now facing 42,700 U.S. plaintiffs blaming its glyphosate-based weedkillers for their cancer, more than twice the tally in July, raising the stakes in the group's efforts to reach a settlement.

"This significant increase is clearly driven by the plaintiff-side television advertising spend which is estimated to have roughly doubled in the third quarter compared with the entire first half of the year," Bayer, which last year acquired Monsanto (NYSE:MON) for $63 billion, said as it reported third-quarter profit grew in line with expectations.

"The number of lawsuits says nothing about their merits," it said, adding the company was still constructively engaged in a mediation process ordered by a federal judge.

Bayer, the inventor of aspirin and owner of Yasmin birth control and Claritin allergy relief brands, is widely expected to eventually buy itself out of the litigation wave, with analysts estimating the size of a future settlement at $8-$12 billion.

Many of them, however, see a knock-down share price reflecting market expectations for the lawsuits to cost as much as $20 billion.

The stock has lost about 30% in value since last August, when a California jury in the first such lawsuit found Monsanto should have warned of the alleged cancer risks associated with its glyphosate-based weedkillers such as Roundup.

Bayer shares were up 0.8% at market open at 0800 GMT. The German group had earlier this month prepared investors for a surge in cases, saying the prospect of a settlement was fanning mass tort lawyers' efforts to recruit plaintiffs.

Bayer, which says regulators and extensive research have found glyphosate to be safe, is banking on U.S. appeals courts to reverse or tone down the first three court rulings that have so far awarded tens of millions of dollars to each plaintiff.

Third-quarter adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) for the group rose 7.5% to 2.3 billion euros ($2.6 billion), in line with market expectations. They were helped by higher sales of crop protection chemicals, seeds and consumer healthcare products.

It said its new 2019 guidance confirmed its previous one, except for stripping out its animal health division and a stake in chemical park operator Currenta being divested, as well as a currency burden of about 100 million euros.

The drugs and pesticides maker is now expecting 11.5 billion euros in full-year EBITDA before special items, down from 12.2 billion euros estimated in July.

Bayer says U.S. plaintiffs on glyphosate more than double since July
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email